Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, Careggi University Hospital, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Urologia. 2022 Aug;89(3):358-362. doi: 10.1177/03915603221077599. Epub 2022 Feb 18.
To evaluate the efficacy and tolerability of a complementary and alternative medicine (CAM) called Kubiker (Naturmed, Montegranaro, FM, Italy), consisting of vitamins (C and D), herbal products (cucurbita maxima, capsicum annum, polygonum cuspidatum), and amino acid L-Glutamine, as first line treatment of (OAB).
According to institutional protocols, data on patients addressing to a tertiary referral centre for OAB symptoms were recorded. OAB was evaluated through validated questionnaires including ICIQ-SF, USS, and OAB-q-SF. Patients with previous antimuscarinic or β3 agonist treatment, neurological disease or pathologies which may mimic OAB, including infections, were excluded. Only unobstructed patients were considered and were given CAM twice daily for 12 weeks. After treatment, symptoms were re-evaluated repeating previous questionnaires and PGI-I was given to evaluate perceived improvement.
A total of 41 patients were evaluated and 35 respected inclusion criteria and were enrolled. All subjects had a full compliance and adherence with CAM medication intake. The median patient's age was 65 (56-73). Male were 8 (22.9%) while females were 27 (77.1%). Median baseline OAB-q SF and ICIQ-SF scores were 18 (15-25) and 9 (6-13), respectively. After treatment, 85.7% patients had a clinical benefit, with a significant reduction of OAB symptoms, also according to USS ( < 0.01). The median OAB-q SF and ICIQ-SF scores were 10 (7-15) and 6 (0-8) ( < 0.01). CAM was successful with an improvement in subjective patient's satisfaction, with a median PGI-I score of 2 (1-3). Patients (men and women) who still had UUI after 3 months CAM medication were eight (22.8%), and among them, those who did not refer any therapeutic benefit were five (14.3%).
According to our study, CAM may be useful medication for a first line treatment of uncomplicated idiopathic OAB cases, providing a nonnegligible effects on symptoms. However, further studies are mandatory to draw definitive conclusions.
评估一种名为 Kubiker（Naturmed，Montegranaro，FM，意大利）的补充和替代医学（CAM）的疗效和耐受性，该疗法包含维生素（C 和 D）、草药产品（南瓜、辣椒、虎杖）和氨基酸 L-谷氨酰胺，作为 OAB 的一线治疗方法。
根据机构方案，记录了因 OAB 症状到三级转诊中心就诊的患者数据。通过经过验证的问卷评估 OAB，包括 ICIQ-SF、USS 和 OAB-q-SF。排除了有先前抗毒蕈碱或β3 激动剂治疗、神经系统疾病或可能模仿 OAB 的病理的患者，包括感染。仅考虑未阻塞的患者，并给予 CAM 每日两次，持续 12 周。治疗后，通过重复先前的问卷重新评估症状，并给予 PGI-I 评估感知改善。
共评估了 41 名患者，其中 35 名符合纳入标准并被纳入。所有患者均完全遵守和坚持 CAM 药物摄入。患者的中位年龄为 65（56-73）岁。男性 8 例（22.9%），女性 27 例（77.1%）。基线时 OAB-q SF 和 ICIQ-SF 评分中位数分别为 18（15-25）和 9（6-13）。治疗后，85.7%的患者有临床获益，OAB 症状显著减轻，USS 也有显著改善（<0.01）。OAB-q SF 和 ICIQ-SF 评分中位数分别为 10（7-15）和 6（0-8）（<0.01）。CAM 成功，患者主观满意度提高，PGI-I 评分中位数为 2（1-3）。在 CAM 药物治疗 3 个月后仍有 UUI 的患者有 8 例（22.8%），其中 5 例（14.3%）表示没有任何治疗获益。
根据我们的研究，CAM 可能是治疗单纯性特发性 OAB 病例的一线药物，对症状有显著的治疗作用。然而，还需要进一步的研究来得出明确的结论。
